Genetic polymorphisms of interleukin 28-B play an important role in response to treatment of chronic hepatitis C

doi:10.3969/j.issn.1006-7795.2012.03.011

Journal of Capital Medical University ›› 2012, Vol. 33 ›› Issue (3): 334-337.doi: 10.3969/j.issn.1006-7795.2012.03.011

• 丙型肝炎宿主基因型与检测 • Previous Articles Next Articles

Genetic polymorphisms of interleukin 28-B play an important role in response to treatment of chronic hepatitis C

TONG Xiao-fei, YOU Hong

Liver Research Center, Beijing Friendship Hospital, Capital Medical University, Beijing 100050, China

Received:2012-02-14 Revised:1900-01-01 Online:2012-06-21 Published:2012-06-21

Abstract

Abstract: The current standard of care for chronic infection with hepatitis C virus is pegylated interferon-alfa(PEG-IFN) and ribavirin (RBV).Genetic variation in interleukin 28-B ( IL-28B ) play an important role in treatment response of chronic hepatitis C. It may be a strong predictor for the therapy of interferon. This paper discusses the significance of IL-28B in the therapy of chronic hepatitis C through the relationship between IL-28B and treatment response with its possible mechanism.

Key words: hepatitis C, genome-wide association study, interleukin 28-B, interferon-λ, interferon-α

CLC Number:

R 512.6⁺3

TONG Xiao-fei;YOU Hong. Genetic polymorphisms of interleukin 28-B play an important role in response to treatment of chronic hepatitis C[J]. Journal of Capital Medical University, 2012, 33(3): 334-337.

[1]	Han Jinyu, Guo Jingjing, Meng Huan, Chen Jin, Wang Yajie. Methodology of the optimal signal-to-cutoff value by chemiluminescence immunoassay of the positive predictive value of hepatitis C antibody ≥ 95% and the discussion of importance [J]. Journal of Capital Medical University, 2024, 45(1): 156-162.
[2]	Wu Yanhua, Wang Peigang, An Jing. Genetic engineering technology makes viruses no more mystery—Introduction of The Nobel Prize in Physiology or Medicine 2020 [J]. Journal of Capital Medical University, 2020, 41(6): 1010-1013.
[3]	Li Yuzheng, Zhang Ting, Wang Xiaomin. The 2016 Lasker Awards [J]. Journal of Capital Medical University, 2016, 37(5): 703-710.
[4]	Liu Chen. Influencing factors and nursing intervention on the compliance to antiviral therapy of patients with hepatitis C [J]. Journal of Capital Medical University, 2015, 36(3): 501-504.
[5]	CHENG Jun. Progress in studies on resistance to direct-acting antiviral agents in patients with chronic hepatitis C virus infection [J]. Journal of Capital Medical University, 2012, 33(4): 530-533.
[6]	CONG Rui;TONG Xiao-fei;LIU YOU Hong. Genetic variation in IL-28B and spontaneous clearance of hepatitis C virus [J]. Journal of Capital Medical University, 2012, 33(3): 326-329.
[7]	LIANG Qi;JIAO Yan-mei;JI Yun-xia;LI Tian;WU Hao;ZHANG Guo-yuan;TANG Zhong. Double negative T cells and lymphocyte subtype in chronic hepatitis C [J]. Journal of Capital Medical University, 2012, 33(2): 214-217.
[8]	LIANG Hong-xia, YU Zu-jiang, ZHANG Qian, LI Zhi-qin, PAN Yan-feng, LI Juan, JIANG He-qing, LI Jian-sheng, HE Yun. Influences of HCV Infection on Incidence of Occult HBV Infection in Patients Infected with HIV-1 [J]. Journal of Capital Medical University, 2011, 32(2): 190-193.
[9]	SHAN Yuan;HUO Na;ZHANG Ai-qiu;WANG Li-fen;LU Hai-ying;XU Xiao-yuan. Impact of Alcohol Drinking on the Clinical Progression and Outcome of Patients with Chronic Hepatitis C [J]. Journal of Capital Medical University, 2009, 30(6): 795-798.
[10]	REN Shan;CHEN Xin-yue. Progress in Studies on Mechanism of Hepatitis C Virus Resistance to Interferon Treatment [J]. Journal of Capital Medical University, 2009, 30(6): 799-804.
[11]	WANG Li-fen;ZHANG Ai-qiu;SHAN Yuan;HUO Na;LU Hai-ying;WU Chi-hong;XU Xiao-yuan. Glycometabolism in Patients with Chronic Hepatitis C and Their Risk Factors [J]. Journal of Capital Medical University, 2009, 30(6): 791-794.
[12]	HE Zhi-min;ZHAO Yan;ZHANG Yong-hong;MA Li-na;SHI Ling-xian;JIN Yi;ZHANG Xiao-dan;CHEN Xin-yue. Differentiations of CD8⁺ T-cell before Treatment Are Associated with the Rapid Virological Response to Antiviral Therapy in Patients Chronically Infected with Hepatitis C Virus [J]. Journal of Capital Medical University, 2009, 30(6): 775-779.
[13]	HUANG Yan-xiang;CHEN Xin-yue;LIN Zun-hui;JIN Hai-ying;MA Li-na;XIE Fang;GUO Xiang-hua;SHI Hong-lin. Clinical Study on the Efficacy of Pegylated Interferon Alpha-2a Plus Ribavirin in Patients with Hepatitis C Virus and Hepatitis B Virus Coinfection [J]. Journal of Capital Medical University, 2009, 30(6): 784-787.
[14]	DUAN Zhong-hui;LI Zhuo;YU Hong-wei;MENG Qing-hua. Association of the Severity of Chronic Hepatitis C with TNF-α Promoter Gene Polymorphism and Level of Serum TNF-α [J]. Journal of Capital Medical University, 2009, 30(3): 381-384.
[15]	Zhang Yonghong;Wu Hao;Jiang Yan;Chen Xinyue;Xiao Yao;Xu Lianzhi. Effect of HCV Infection on HAART in HIV/AIDS Patients [J]. Journal of Capital Medical University, 2004, 25(3): 329-331.

Genetic polymorphisms of interleukin 28-B play an important role in response to treatment of chronic hepatitis C

PDF

Knowledge

Cited

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments